Amneal Pharmaceuticals (AMRX) EPS (Basic) (2018 - 2026)

Amneal Pharmaceuticals' EPS (Basic) history runs 9 years deep, the most recent figure standing at $0.2 for Q1 2026.

• In Q1 2026, EPS (Basic) rose 400.0% year-over-year to $0.2; the TTM figure through Mar 2026 stood at $0.39 (up 1075.0% YoY), while the FY2025 annual figure was $0.23, up 160.53% from the prior year.
• EPS (Basic) was $0.2 for Q1 2026 at Amneal Pharmaceuticals, up from $0.11 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $0.2 in Q1 2026 to a low of -$0.8 in Q2 2022.
• Historically, EPS (Basic) has averaged -$0.07 across 5 years, with a median of $0.01 in 2025.
• Biggest YoY gain for EPS (Basic) was 400.0% in 2023; the steepest drop was 1833.33% in 2023.
• A 5-year view of EPS (Basic) shows it stood at -$0.03 in 2022, then slumped by 1833.33% to -$0.58 in 2023, then soared by 82.76% to -$0.1 in 2024, then surged by 210.0% to $0.11 in 2025, then jumped by 81.82% to $0.2 in 2026.
• The last three EPS (Basic) figures came in at $0.2 (Q1 2026), $0.11 (Q4 2025), and $0.01 (Q3 2025), per Business Quant data.